会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明授权
    • Rec 2 kinase
    • Rec 2激酶
    • US06210916B1
    • 2001-04-03
    • US09587436
    • 2000-06-05
    • Pamela A. HavreMichael C. RiceWilliam K. HollomanEric B. Kmiec
    • Pamela A. HavreMichael C. RiceWilliam K. HollomanEric B. Kmiec
    • C12Q148
    • C12N9/1205C12N2799/026C12Q1/48
    • The invention includes a method of phosphorylating a serine containing substrate by incubating the substrate with ATP and an enzyme that is hsRec2 or muRec2 or a derivative thereof. The natural substrates of the kinase activity of Rec2 are the cell cycle control proteins such as p53 and cyclin E. The over expression of Rec2 is known to cause cell-cycle arrest and apoptosis and the invention discloses that these effects are kinase mediated. Accordingly, the invention provides a method of assessing antagonists and agonists of Rec2, which antagonists and agonists would have pharmacological activity. The invention further discloses that there is specific binding between hsRec2 and at least three cell cycle control proteins: p53, PCNA and cdc2.
    • 本发明包括通过用ATP孵育底物和使用hsRec2或muRec2或其衍生物的酶来磷酸化含丝氨酸的底物的方法。 Rec2的激酶活性的天然底物是细胞周期控制蛋白如p53和细胞周期蛋白E.已知Rec2的过度表达引起细胞周期阻滞和凋亡,本发明公开了这些作用是激酶介导的。 因此,本发明提供了一种评估Rec2的拮抗剂和激动剂的方法,该拮抗剂和激动剂将具有药理活性。 本发明还公开了hsRec2与至少三种细胞周期控制蛋白之间的特异性结合:p53,PCNA和cdc2。
    • 6. 发明授权
    • REC2 kinase
    • REC2激酶
    • US06174694B1
    • 2001-01-16
    • US09157603
    • 1998-09-21
    • Pamela A. HavreMichael C. RiceWilliam K. HollomanEric B. Kmiec
    • Pamela A. HavreMichael C. RiceWilliam K. HollomanEric B. Kmiec
    • C12Q148
    • C12N9/1205C12N2799/026C12Q1/48
    • The invention includes a method of phosphorylating a serine containing substrate by incubating the substrate with ATP and an enzyme that is hsRec2 or muRec2 or a derivative thereof. The natural substrates of the kinase activity of Rec2 are the cell cycle control proteins such as p53 and cyclin E. The over expression of Rec2 is known to cause cell-cycle arrest and apoptosis and the invention discloses that these effects are kinase mediated. Accordingly, the invention provides a method of assessing antagonists and agonists of Rec2, which antagonists and agonists would have pharmacological activity. The invention further discloses that there is specific binding between hsRec2 and at least three cell cycle control proteins: p53, PCNA and cdc2.
    • 本发明包括通过用ATP孵育底物和使用hsRec2或muRec2或其衍生物的酶来磷酸化含丝氨酸的底物的方法。 Rec2的激酶活性的天然底物是细胞周期控制蛋白如p53和细胞周期蛋白E.已知Rec2的过度表达引起细胞周期阻滞和凋亡,本发明公开了这些作用是激酶介导的。 因此,本发明提供了一种评估Rec2的拮抗剂和激动剂的方法,该拮抗剂和激动剂将具有药理活性。 本发明还公开了hsRec2与至少三种细胞周期控制蛋白之间的特异性结合:p53,PCNA和cdc2。